AU606124B2 - Method for inhibiting the release of histamine - Google Patents

Description

luG I.LJ 1.4I1 1.6 1-3 11111 _111_1_.6 'r-z i A -1 I:

I

M 1049508 FORM COMMONWEALTH OF AUSTRALIA PATENTS ACT 1952 COMPLETE SPECIFICATION

(ORIGINAL)

FOR OFFICE USE: This document contains the amendments made under Section 49 and is correct for printing Class Int Class S Complete Specification Lodged: Accepted: Published: Priority: p Related Art: Name and Address of Applicant: Vipont Pharmaceutical, Inc.

UNITED STATES OF AMERICA Address for Service: Spruson Ferguson, Patent Attorneys Level 33 St Martins Tower, 31 Market Street Sydney, New South Wales, 2000, Australia 1 Complete Specification for the invention entitled: Method for Inhibiting the Release of Histamine The following statement is a full description best method of performing it known to me/us of this invention, including the f1 5845/3 -111 -11 -11

ALLU'-'

ABSTRACT

The present invention deals with the inhibition of histamine release from mammalian mast cells by contacting such cells with sanguinarine, a benzophenanthridine alkaloid.

o 0, o 0 4 0440 4444 ~4440O 944040 o 4 044004 4 0

II

4 1 4 0, 4 *0 4 51 4 I~ I 0 *411 1(11

I

1141 11 4 4 4 4 4 1180P/SBR/JS METHOD FOR INHIBITING THE RELEASE OF HISTAMINE FIELD OF THE INVENTION The present invention relates to a method for controlling the release of histamine from mast cells BACKGROUND OF THE INVENTION Benzo-c-phenanthridine alkaloids can be extracted alkaloids can be extracted from plants of the familiar Pavaversease, Fumariaceae, and Berberidaceae. Some of the plants of these familiar includes Sanguinaria canadensis, Macleaya cordata, Bocconia frutescens, Carydalis sevctcozii, C.

ledebouni, Argemone mexicanus, and Chelidonium majus. Among the most important benzo-c-phenanthridine alkaloids obtained from these plants are sanguinarine, chelirubine, macarpine, allocryptopine, protopine, hemochelidonene, sanguilantine, sanguiribine, and chelerythrine.

The best known of these alkaloids is sanguinarine, which has been extracted from the Sanguinaria canadensis plant (otherwise known as 0o"o bloodroot, teteroot, redroot, puccoon, etc.) a perennial herb native to oo North America. The sanguinaria plant and its juices have been used for S various puoposes in pre-historic and historic times. The plants have been used, in particular, as a folk remedies. The plants have generally been used while, either undried (fresh) or dried, and the usual procedure is to powder the dried plant and mix it with a carrier. This folk remedy has been tried for such conditions as bronchitis, dysentery, ringworm and a substantial list of other ailments.

The pure chemicals sanguinarine, chelerythrine, protopine, o 0 chelerubine, berberine, chelilutine, sanguilatine, macarpine, sanguirubine 0 and allocryptopine can be isolated from plants other than Sanguinaria.

They are also available, although rarely, from some chemical supply houses. Semi-purified forms of the alkaloids are commercially available, and these are generally referred to as sanguinarine nitrate and sanguinarine sulfate. These compounds are the salts of the mixed alkaloids of the plant Sanguinaria: mainly sanguinarine, chelerythrine, and Sprotopine. While few references can be found in the literature regarding the usage of any of the pure benzophenanthridine alkaloids, plants containing such compounds have been used for a wide variety of medical aliments.

The alkaloid sanguinarine in solution has been shown to have some antifungal and antiprotozoan properties. The sanguinarine is applied as an emulsion topically to fungal infections. The antibacterial activity of I sanguinarine has been found to vary with attached radicals, and various SLS salts of sanguinarine have been shown to have some activity. The S8 P/SBR/JS L .I -2hydrochloride and the sulfate salts have been found to have some activity against certain bacteria at certain concentrations. Sanguinarine nitrate is reported to have some bacteriostatic action against various types of bacteria.

The use of an extract of Sanguinaria canadensis as an ingredient in oral cleaning preparation, in particular, toothpaste, is disclosed in U.S.

Patent No. 4,145,412.

The extract may be produced by treating a finely cut or ground bloodroot with an organic solvent, such as methanol, acidulated methanol, acidulated ethanol, acidulated methanol-water solutions, acidulated ethanol-water solutions, and mixtures thereof.

o The bloodroot is thoroughly stirred with several volumes of the 0 a, solvent, and is maintained in the solvent for a prolonged time 24 09 0 hours or more, at a temperature of about 60 0 In accordance with one 1° 1 technique the solution can be filtered and the solvent evaporated. The I "0 residue can then be dissolved in chloroform), treated with concentrated hydrochloric acid, filtered and then dried. The dried extract may be taken up in warm glycerine (65 0 for mixing with a carrier. In accordance with other techniques, after the plant has been extracted with solvent, the extract can be precipitated with an acid salt which is soluble in the solvent, the precipitated salt is redissolved in water, acid is added to form a precipitate, and the precipitate is collected.

SUMMARY OF THE INVENTION The present invention therefore deals with the inhibition or suppression of histamine release from mammalian mast cells by contacting such cells with a benzophenanthridine alkaloid, such as sanguinarine. In giving evidence of the invention it has been discovered that Sanguinarine (1-10 p. M) inhibited histamine release stimulated by compound 48/80, a well known histamine release agent. This inhibitory action was also found when histamine release was induced by other known histamine releasers, such as concanavalin A, histldine-rich polypeptide (Fraction-A), and calciumionophore A23187, while this was not the case with a well known surfactant Triton X-100 (octylphenoxy polyethryethanol). It is believed that the sanguinarine acts as a stabilizer of the membrane of the mast cells.

RA, According to a first embodiment of this invention there is provided a T r method for inhibiting the release of histamine from mammalian mast cells LS w /0899 /0899v 3 -3comprising contacting said mast cells with a histamine inhibiting amount of benzo-c-phenanthridine alkaloid.

According to a second embodiment of this invention there is provided a method comprising inducing the release of histamine from mammalian mast cells, and then controlling said release by contacting said mast cells with a histamine .t4ieng amount of benzo-c-phenanthridine alkaloid.

DETAILED DESCRIPTION OF THE INVENTION Sanguinarine heretofore stated is a benzophenanthridine alkaloid extracted, for example, from the rhizomes of the plant Sanguinaria candensis; as seen in American Pharmaceutical Association, National Formulary, 7th Revision (1940) pp. 191, 368 and 416. It has been shown that sanguinarine exhibits various biological activities such as antimicrobial activity; as seen in Johnson, C.C. Johnson, G. and Poe, C.F.

(1952) Acta Pharmacol. Toxicol. 8, 71-78; and Dzink, J.L. and Socransky, S.S. (1985) Antimicrobial Agents and Chemother. 27, 663-665. There is S evidence that it also inhibits Na, K-ATPase, as seen in Straub, K.D. and Carver, P. (1970) Biochem. Biophys. Rec. Commun. 62, 913 and 922. It has also shown cation-transport, as seen in Cala, Norby, J.G. and Toteson, D.C. (1982) J. Membrane Biol. 64,23-31. It has been shown to '""210 inhibit yeast respiration, as seen in Vallejos, R.H. and Roveri, O.A.

(1972) Blochem. Pharmacol. 21, 2179-3182. More recently it has also been o .o found that sanguinarine has antiplaque activity as seen in Southard, G.L., Boulware, Walborn, Groznik, Throne, E.E. and Yankell, S.L. (1981). Am. Dent. Assoc. 108, 338-341. Sanguinarine also has anti-inflammatory activity as demonstrated in Lenfeld, Kroutil, M., Marsalek, Slavik, Preininger, V. and Simanak, V. (1981) Planta Med.

S43, 161-165. Finally as perhaps the latest finding it is now known that sanguinarine demonstrates significant inhibition of bone resorption in vitro, as seen in Cowen, Sakamoto, Sakamoto, M. and Southard, G.L. (1986) J. Dent. Res. 65, 246.

In exemplifying the invention, mast cells were isolated from the peritoneal fluid of male Wistar rat as described in Sugiyama, K. (1971) Japan J. Pharmacol. 21, 209-226. The mast cells were suspended in a phosphate buffered saline solution consisting of 154 mM sodium chloride.

2.7 mM potassium chloride, 0.9 mM calcium chloride, 6.7 mM RA KH 2

PO

4 -Na 2

HPO

4 (pH and 0.01% bovine serum albumin obtained from Sigma.

/0899v -4- EXAMPLE 1 For the determination of histamine release and its inhibition by sanguinarine, mast cells at a cell density of 10 5 cells/mi suspended in ml of phosphate-buffered saline, were incubated at 37 0 C for 10 minutes with histamine releasers, more about which is stated below. Sanguinarine was added 5 minutes before the specific histamine releaser. After the action was terminated by the addition of 1.5 ml of ice-cold phosphate-buffered saline solution, the samples were centrifuged at 2,000 rpm for 15 minutes. The histamine in the supernatants and precipitates was determined according to the method of Shore, Burkhalter, A. and Cohn N.H. (1959) J. Pharmacol. Exp Ther. 127, 182-186. Release of histamine was t expressed as a percentage of the total cell content. Percentages of o I 0 o n 0 *t 0 0 0 0 0 0 SL S KEH/0899v inhibition by sanguinarine were measured according to the following equation: Inhibition Histamine release from mast cells (with Sanquinarine) S Histamine released from mast cells (without Sanguinarine) The sanguinarine chloride was provided from Vipont Laboratories Inc. and is manufactured in the manner disclosed in U.S. patent Application S.N.

822,967 filed January 28, 1986 and is incorporated herein in its entirety by reference. Histidine-rich po Weptide fraction A, known as HRP(F-A) was purified from human saliva in accordance with the procedure of Sugiyama, Suzuki, Y and Furuta, H (1985) Life Sciences. 37, 475-480. The comparison was carried out with known histamine releasers, namely, 48/80; Concanavalin A; calcium-ionophore A23187. These releasers may be obtained from Sigma Co.

In the results it was noted that 48/80 induced histamine release from mast cells was inhibited by sanguinarine in a dose-dependent manner as can o o° be seen from Figure 1; wherein the IC 50 (inhibition concentration) was oO about 2 p M. Histamine release induced by sanguinarine itself was not 0 0 a apparent in a concentration less than 100 p M. The inhibitory effect of S sanguinarine was also observed in the histamine release stimulated by Concanavalin A, histidine-rich polypeptide and Ca-ionophore A 23187, but not in the histamine release stimulated by Triton X-100 (Table 1).

It has been recognized that histamine release stimulated by compound 48/80 from mast cells is initiated by the fusion of plasma and granule membrane (exocytosis) as discussed by Uvnas, B. (1974) Fed. Proc. 33, S 2172-2176. Concanavalin A. stimulates histamine release from mast cells in S the presence of phosphatidylserine and calcium ions, discussed by Sugiyama, Sasaki, J. and Yamasaki, H. (1975) Japan. J. Pharmacol. 25, 485-487.

Calcium-ionophore A 23187 also releases histamines dependent upon the external Calcium ions. On the other hand, histamine release evoked by compound 48/80 and histidine-rich polypeptide is independent of extracellular calcium. Sanguinarine markedly inhibited histamine release induced by a variety of different agents except Triton X-100 (a detergent). These observations suggest that sanguinarine may not inhibit a calcium-dependent mechanism required for the initiation of histamine release.

It has been reported in Pearce, Atkinson, Ennis, M., Trench, Weston, P.M. and White, J.R. (1979) in "The Mast Cell" (Pepys, 3. and Edwards, ed.) pp 69-75, Pitman Medical Publishing Co. Ltd, SLS i England that anti-allergy drugs such as theophylline and cromoglycate r o/J 180P/SBR/JS i: inhibited the histamine release produced by compound 48/80, calicumionophore A23187, and basic peptide 401, (a bee venom); the latter mentioned in the immediately forgoing literature article. They indicated that the IC 50 of these drugs was in a O.O0-lmM concentration range.

These values are about 10 to 100 times less active than sanguinarine inhibited histamine release. It has also been shown in Yamasaki, H. and Saeki K. (1967) Arch, int. Pharmacodyn. 168, 166-179 that compound 48/80 induced histamine release was inhibited by the anti-inflammatory agents, indomethacin, sodium salicylate, and hydrocortisone. The IC50 for those agents was 75 p M, 1.6mM and 2.1 mM, respectively. Thus, in comparison with the IC 50 of these drugs, sanguinarine inhibits histamine release at very low concentrations.

It is pointed out that the mechanisms by which sanguinarine inhibits histamine release are at present unknown. It is speculated that sanguinarine acts as a stabilizer of membrane activities relating to the physical chevtccl nature of exocytosis involving transfer of the inner granules to the outside.

TABLE 1: Inhibition by Sanguinarine of Histamine Release from Rat Isolated Mast Cells o 0 1a 0 00 9Q1 090 .6 *i i 0 ii ,a *r I i 30 4 0 Releasing agents Sanguinarine Histamine (Conc.) (pM) Release Inhibition Compound 48/80 72.3 (0.5 p g/ml) 5 15.4 78.7 Con A* 62.9 (10 pg/ml) 5 27.3 56.6 A23187 57.7 (1 p M) 5 21.1 63.4 HRP -57.6 (16 p M) 5 17.6 69.4 Triton X-100 84.8 (0.01 5 93.8 -10.6 *in the presence of phosphatidylserine (10 p g/ml) With regard to Figure 1, inhibition by sanguinarine of histamine release induced by compound 48/80 is shown. The mast cells were incubated at 370C for 10 minutes with and without compound 48/80 in the presence of sanguinarine in varying concentrations. Sanguinarine with compound 48/80 (0.5 p g/ml), Sanguinarine without compound 48/80.

U

1180P/SBR/JS

Claims (8)

1. A method for inhibiting the release of histamine from mammalian mast cells comprising contacting said mast cells with a histamine inhibiting amount of benzo-c-phenanthridine alkaloid.

2. The method of claim 1 wherein the benzo-c-phenanthridine alkaloid is sanguinarine.

3. The method of claim 2 wherein the sanguinarine is in a diluent.

4. A method comprising inducing the release of histamine from mammalian mast cells, and then controlling said release by contacting said mast cells with a histamine/iRnduing amount of benzo-c-phenanthridine alkaloid. a",9

5. The method of claim 4 wherein the benzo-c-phenanthridine ao alkaloid is sanguinarine.

6. The method of claim 5 wherein the sanguinarine is in a diluent.

7. A method for inhibiting the release of histamine from mammalian mast cells, substantially as herein described with reference to Example 1 but excluding comparative examples.

8. A method comprising inducing the release of histamine from a o0 mammalian mast cells, and then controlling said release by contacting said mast cells with a histamineI inductng amount of benzo-c-phenanthridine alkaloid, substantially as herein described with reference to Fig. 1 and U ,Example 1 but excluding comparative examples. DATED this THIRTIETH day of AUGUST 1990 o Vipont Pharmaceutical, Inc. toy 0. Patent Attorneys for the Applicant SPRUSON FERGUSON i E -VV LSU SA._ KEH/0899v